24 August 2021: Clinical Research
Different Doses of Nalbuphine Combined with Dexmedetomidine in Laparoscopic Oophorocystectomy
Xiaofen Liu ABCDEF , Jie Song BCDF , Yang Zhang BCDF , Ye Zhang BCDF , Xianwen Hu CDFG*DOI: 10.12659/MSM.930197
Med Sci Monit 2021; 27:e930197
Table 4 Serum levels of IL-1β and IL-6 before and after surgery in different groups of patients (pg/mL).
| Variables | LND, n=55 | MND, n=54 | HND, n=55 | Control, n=55 | P value |
|---|---|---|---|---|---|
| IL-1β, before | 5.38±2.53 | 5.81±2.87 | 5.23±2.85 | 5.87±2.51 | 0.526 |
| IL-1β, after | 31.13±9.00c | 26.72±8.53c | 20.22±5.71a | 40.19±12.47a | |
| IL-6, before | 5.24±2.44 | 5.83±2.46 | 5.71±2.74 | 5.50±2.53 | 0.637 |
| IL-6, after | 34.80±12.44c | 30.87±9.02c | 21.91±6.99a | 43.77±12.96a | |
| a b c d IL-1β – interleukin-1β, IL-6 – interleukin-6; LND – low-dose nalbuphine and dexmedetomidine; MDN – middle-dose nalbuphine and dexmedetomidine; HND – high-dose nalbuphine and dexmedetomidine. | |||||